Charles River Endosafe Trillium rCR cartridges

ProGastro™ Cd Gives Labs a User-Friendly Molecular Option for C.diff

Prodesse, Inc. has received 510(k) clearance from the FDA to market its ProGastro™ Cd Assay as an in vitro diagnostic product in the United States.

The clearance came in less than 90 days from submission. ProGastro Cd uses real-time PCR technology; it is simple to use and easily integrates into existing lab workflow. The product has been optimized for the use of automated extraction technology so that its inhibition rate is extremely low. A result can be obtained in as little as 3 hours using the assay.

Clinical trials were conducted at three clinical laboratories in the US. They reported that ProGastro Cd was easy-to-use and that it rapidly and accurately detected toxigenic strains of Clostridium difficile.

In its clinical trials, ProGastro Cd detected 43% more positives than did the current gold standard, the cell cytotoxin assay. Genetic sequencing confirmed that over 90% of the additional positives detected by ProGastro Cd were accurate. In addition, there were no inhibited samples reported by the three clinical sites.

NOTE: This item is from our 'historic' database and may contain information which is not up to date.

Source : Prodesse Inc. View archived contact details

Posted on April 20, 2009

Neogen introducing Veratox VIP for Walnut

RapidChek Total Protein - Detect as low as 3 microgram protein residue in 30 seconds

PDA Alternative Microbiological Methods Workshop 2024

Download the rapidmicrobiology media kit 2024 and discover what your marketing team can achieve

Pharma Microbiology Congress 2024

Get our eNewsletter
Over 7,000 microbiology professionals get our weekly eNewsletter - subscribe now and find out why!